Open Access Repository

Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to II clinical trials

Wu, J, Zhu, Z, Yu, Q and Ding, C ORCID: 0000-0002-9479-730X 2019 , 'Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to II clinical trials' , Expert Opinion on Investigational Drugs, vol. 28, no. 12 , pp. 1113-1123 , doi: 10.1080/13543784.2019.1692812.

Full text not available from this repository.

Abstract

Introduction: Rheumatoid arthritis (RA) is a chronic, refractory disorder caused by autoimmunity in the synovial joints. Disease-modifying anti-rheumatic drugs (DMARDs) and biologicals offer remission in only two-thirds of RA patients within 3 months, hence new therapeutic approaches are necessary. Tyrosine kinase inhibitors (TKIs) are newly developed small molecule drugs which have demonstrated encouraging results in this disease.Areas covered: The key findings from phase I and II clinical trials that have investigated the use of novel TKIs in the treatment of RA are discussed. We examined the literature published between January 2014 to January 2019 using electronic databases including PubMed, Web of Science, Medline, Embase, and Google Scholar. Additional information about phase I and II trials on the ClinicalTrial.gov website up to January 2019 was also retrieved.Expert opinion: JAK inhibitors are promising drugs with sound efficacy and acceptable safety and may be beneficial to patients who do not respond to DMARDs and biologicals. The response rates among RA patients to TKIs are diverse; genetic and environmental factors may be involved in the varying responses which are closely related to the pathogenesis of RA. Future studies may reveal the underlying mechanisms of resistance and non-response.

Item Type: Article
Authors/Creators:Wu, J and Zhu, Z and Yu, Q and Ding, C
Keywords: Bruton’s tyrosine kinases, Janus kinase, rheumatoid arthritis, disease-modifying anti-rheumatic drugs, spleen tyrosine kinases, tyrosine kinase inhibitor
Journal or Publication Title: Expert Opinion on Investigational Drugs
Publisher: Ashley Publications Ltd
ISSN: 1354-3784
DOI / ID Number: 10.1080/13543784.2019.1692812
Copyright Information:

Copyright 2019 Informa UK Limited, trading as Taylor & Francis Group

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP